Zeo ScientifiX grants options to major holder
Zeo ScientifiX, Inc. reported stock option awards to a major holder and related entity.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Zeo ScientifiX, Inc. reported stock option awards to a major holder and related entity. The filing shows grants of options under the company’s 2021 Equity Incentive Plan, exercisable at an exercise price of $1.67 per share and expiring on June 10, 2036.
Footnotes explain that the options were issued to Greyt Ventures, LLC, a principal stockholder and consultant owned by a trust for which Wendy Grey is trustee. One grant vests upon achieving performance milestones, while another vested in full at the grant date, and both are exercisable on a cashless basis with anti-dilutive features tied to large future issuances.
Insider Trade Summary
Grant/Award: 1,250,000 shares
Grant/Award
2 txns
Insider
Grey Wendy, Greyt Ventures, LLC
Role
10% Owner | 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options | 625,000 | $0.00 | $0.00 |
| Grant/Award | Stock Options | 625,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options — 1,250,000 contracts (Indirect, See Footnote)
Footnotes (3)
- F1. Represents the grant of stock options to purchase shares of the Issuer's common stock under its 2021 Equity Incentive Plan (the "2021 Plan"). The options vest upon the achievement of certain performance milestones, are exercisable on a "cashless basis" during the period commencing on the date they vest and ending ten (10) years from the award date, and are subject to the other terms and conditions of the 2021 Plan. The options are antidilutive for any future transaction that provides for the issuance of 10% or more of the Company's common stock outstanding on a fully diluted basis.
- F2. Securities issued by Issuer to Greyt Ventures, LLC, a principal stockholder and consultant to the Issuer. Greyt Ventures, LLC is owned by a trust for which Ms. Grey is trustee.
- F3. Represents the grant of stock options to purchase shares of the Issuer's common stock under its 2021 Plan. The options vested in full as of the grant date, are exercisable on a "cashless basis" for a period of ten (10) years from the award date, and are subject to the other terms and conditions of the 2021 Plan.
Key Figures
Exercise price: $1.67 per share
Option term: 10 years
Expiration date: June 10, 2036
+2 more
5 metrics
Exercise price
$1.67 per share
Stock options under 2021 Equity Incentive Plan
Option term
10 years
Options exercisable for ten years from award date
Expiration date
June 10, 2036
Option expiration for reported grants
Anti-dilutive trigger
10% of common stock
Antidilutive for future issuances ≥10% on fully diluted basis
Grant size per entry
625,000 options
Each reported grant of stock options
Key Terms
2021 Equity Incentive Plan, cashless basis, antidilutive, fully diluted basis, +1 more
5 terms
2021 Equity Incentive Plan financial
"Represents the grant of stock options to purchase shares of the Issuer's common stock under its 2021 Equity Incentive Plan"
cashless basis financial
"The options vest upon the achievement of certain performance milestones, are exercisable on a "cashless basis""
An agreement executed on a cashless basis lets a holder convert or exercise a security (like options, warrants, or conversion rights) without paying money upfront; instead the holder receives a smaller number of shares equal in value to what the cash would have purchased. Think of trading a coupon for fewer slices of a cake rather than handing over cash for the full slice. For investors, it affects how much ownership and dilution occur and avoids immediate cash outlays.
antidilutive financial
"The options are antidilutive for any future transaction that provides for the issuance of 10% or more"
fully diluted basis financial
"10% or more of the Company's common stock outstanding on a fully diluted basis"
A fully diluted basis counts every share that could exist if all outstanding options, warrants, convertible securities and other rights were exercised or converted into common stock, showing the maximum number of shares outstanding. For investors this matters because it spreads ownership and earnings across that larger share count, like slicing a pie into every possible piece before deciding how big each investor’s slice will be, which affects per-share value and ownership percentage.
principal stockholder financial
"Securities issued by Issuer to Greyt Ventures, LLC, a principal stockholder and consultant to the Issuer"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Zeo ScientifiX (ZEOX) report in this Form 4?
Zeo ScientifiX reported grants of stock options under its 2021 Equity Incentive Plan. The options were awarded to Greyt Ventures, LLC, a principal stockholder and consultant, with Wendy Grey as trustee of the owning trust, and are exercisable on a cashless basis.
Who received the Zeo ScientifiX (ZEOX) stock options disclosed in this filing?
The stock options were issued to Greyt Ventures, LLC, described as a principal stockholder and consultant to Zeo ScientifiX. Footnotes state Greyt Ventures, LLC is owned by a trust for which Wendy Grey serves as trustee, linking the awards to a ten percent owner.
What are the key terms of the Zeo ScientifiX (ZEOX) option grants?
The options carry an exercise price of $1.67 per share and expire on June 10, 2036. They are exercisable on a cashless basis, were granted under the 2021 Equity Incentive Plan, and remain subject to that plan’s other terms and conditions.
How do the Zeo ScientifiX (ZEOX) options vest for Greyt Ventures, LLC?
One option grant vests upon achieving specified performance milestones, while another vested in full on the grant date. Both sets of options are exercisable on a cashless basis for ten years from the award date, consistent with the 2021 Equity Incentive Plan terms.
What is the anti-dilutive feature mentioned in the Zeo ScientifiX (ZEOX) option grants?
Footnotes state the options are antidilutive for any future transaction that issues at least 10% of Zeo ScientifiX common stock on a fully diluted basis. This means the option grants are structured not to increase dilution if such large future issuances occur.
AI-generated analysis. How Rhea-AI works. Not financial advice.
